Cargando…

250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study

BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in critically ill adults is increasing with no guidelines for antimicrobial prophylaxis. Patients on ECMO are at a high risk for infections, 6.1% of neonates and 20.5% of adults. An Extracorporeal Life Support Organization (ELSO) Infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Aditya, Dhungana, Prabij, Sampathkumar, Priya, Bohman, John K, O’horo, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255444/
http://dx.doi.org/10.1093/ofid/ofy210.261
_version_ 1783373941748793344
author Shah, Aditya
Dhungana, Prabij
Sampathkumar, Priya
Bohman, John K
O’horo, John C
author_facet Shah, Aditya
Dhungana, Prabij
Sampathkumar, Priya
Bohman, John K
O’horo, John C
author_sort Shah, Aditya
collection PubMed
description BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in critically ill adults is increasing with no guidelines for antimicrobial prophylaxis. Patients on ECMO are at a high risk for infections, 6.1% of neonates and 20.5% of adults. An Extracorporeal Life Support Organization (ELSO) Infectious Disease Task Force statement concludes that no additional antibiotic coverage is needed for patients on ECMO. Since patients on ECMO are severely ill, providers tend to prescribe empiric antibiotics. To guide rational antibiotic therapy we introduce an ECMO antimicrobial protocol on July 1, 2014 and report its impact. METHODS: We conducted a retrospective review of 294 patients on ECMO between July 1, 2011 and July 1, 2017. The ECMO antimicrobial protocol was introduced on July 1, 2014. We had a cohort of 133 patients before and 161 patients after the implementation of protocol. We evaluated days of antimicrobial use, antibiotic-free days and days of individual antimicrobial use, adjusted for APACHE scores and ECMO duration. RESULTS: Total days of antimicrobial use after the protocol decreased from 2,508 to 2,186 days (P = 0.01) with statistically significant reduction of individual antimicrobials; vancomycin (407 to 266, P < 0.03), cefepime (196 to 165, P < 0.06), along with reduced days of anidulafungin, caspofungin, fluconazole, meropenem, and daptomycin. However, when adjusted for mean days on ECMO 7 (4–14) before as compared with 5 (3–9.5) after (P < 0.0119), “antimicrobial free days” actually reduced after implementation of the protocol. Early trends of improved stewardship were off-set when time frame and number of patients were increased. Despite this, no difference was seen in rate of nosocomial infections, with increased rates seen for Clostridium difficile (0 vs. 4, P < 0.06). CONCLUSION: “Protocolization” and standardization of antimicrobial recommendations for patients on ECMO led to reduction in the use of specific antibiotics but paradoxically increased overall antibiotic use. We are in the process of emphasizing compliance with this protocol, which will be followed by implementation of a more restrictive protocol. We will do a step wedge randomized control prospective analysis to evaluate compliance differences between the medical and surgical critical care services, and the impact on patient outcomes. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6255444
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62554442018-11-28 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study Shah, Aditya Dhungana, Prabij Sampathkumar, Priya Bohman, John K O’horo, John C Open Forum Infect Dis Abstracts BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in critically ill adults is increasing with no guidelines for antimicrobial prophylaxis. Patients on ECMO are at a high risk for infections, 6.1% of neonates and 20.5% of adults. An Extracorporeal Life Support Organization (ELSO) Infectious Disease Task Force statement concludes that no additional antibiotic coverage is needed for patients on ECMO. Since patients on ECMO are severely ill, providers tend to prescribe empiric antibiotics. To guide rational antibiotic therapy we introduce an ECMO antimicrobial protocol on July 1, 2014 and report its impact. METHODS: We conducted a retrospective review of 294 patients on ECMO between July 1, 2011 and July 1, 2017. The ECMO antimicrobial protocol was introduced on July 1, 2014. We had a cohort of 133 patients before and 161 patients after the implementation of protocol. We evaluated days of antimicrobial use, antibiotic-free days and days of individual antimicrobial use, adjusted for APACHE scores and ECMO duration. RESULTS: Total days of antimicrobial use after the protocol decreased from 2,508 to 2,186 days (P = 0.01) with statistically significant reduction of individual antimicrobials; vancomycin (407 to 266, P < 0.03), cefepime (196 to 165, P < 0.06), along with reduced days of anidulafungin, caspofungin, fluconazole, meropenem, and daptomycin. However, when adjusted for mean days on ECMO 7 (4–14) before as compared with 5 (3–9.5) after (P < 0.0119), “antimicrobial free days” actually reduced after implementation of the protocol. Early trends of improved stewardship were off-set when time frame and number of patients were increased. Despite this, no difference was seen in rate of nosocomial infections, with increased rates seen for Clostridium difficile (0 vs. 4, P < 0.06). CONCLUSION: “Protocolization” and standardization of antimicrobial recommendations for patients on ECMO led to reduction in the use of specific antibiotics but paradoxically increased overall antibiotic use. We are in the process of emphasizing compliance with this protocol, which will be followed by implementation of a more restrictive protocol. We will do a step wedge randomized control prospective analysis to evaluate compliance differences between the medical and surgical critical care services, and the impact on patient outcomes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255444/ http://dx.doi.org/10.1093/ofid/ofy210.261 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Shah, Aditya
Dhungana, Prabij
Sampathkumar, Priya
Bohman, John K
O’horo, John C
250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title_full 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title_fullStr 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title_full_unstemmed 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title_short 250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
title_sort 250. antimicrobial management in extracorporeal membrane oxygenation: the ammo study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255444/
http://dx.doi.org/10.1093/ofid/ofy210.261
work_keys_str_mv AT shahaditya 250antimicrobialmanagementinextracorporealmembraneoxygenationtheammostudy
AT dhunganaprabij 250antimicrobialmanagementinextracorporealmembraneoxygenationtheammostudy
AT sampathkumarpriya 250antimicrobialmanagementinextracorporealmembraneoxygenationtheammostudy
AT bohmanjohnk 250antimicrobialmanagementinextracorporealmembraneoxygenationtheammostudy
AT ohorojohnc 250antimicrobialmanagementinextracorporealmembraneoxygenationtheammostudy